Current and prospective antibody-based therapies in multiple myeloma

Emily Bryer; Christin DeStefano; Dickran Kazandjian

doi:10.1053/j.seminoncol.2021.11.002

Current and prospective antibody-based therapies in multiple myeloma

Emily Bryer, Christin DeStefano^*, Dickran Kazandjian^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Multiple Myeloma (MM) is a hematologic malignancy involving clonal plasma cell proliferation. Unfortunately, MM remains an incurable disease. Over the past five years, the incorporation of novel monoclonal antibodies has synergized with standard of care to improve patient outcomes in both newly diagnosed MM as well as relapsed and refractory MM. This manuscript reviews current and prospective antibody-based treatments including naked monoclonal antibodies, immunoconjugates, and Bi-specific T-cell engagers (BiTE).

Original language	English
Pages (from-to)	41-47
Number of pages	7
Journal	Seminars in Oncology
Volume	49
Issue number	1
DOIs	https://doi.org/10.1053/j.seminoncol.2021.11.002
State	Published - Feb 2022
Externally published	Yes

Keywords

Belantamab
BiTE
Daratumumab
Elotuzumab
Immunoconjugates
Isatuximab
Monoclonal antibody
Multiple myeloma

Access to Document

10.1053/j.seminoncol.2021.11.002

Cite this

@article{a9332f3c688d40b0838e6ad428a690f3,

title = "Current and prospective antibody-based therapies in multiple myeloma",

abstract = "Multiple Myeloma (MM) is a hematologic malignancy involving clonal plasma cell proliferation. Unfortunately, MM remains an incurable disease. Over the past five years, the incorporation of novel monoclonal antibodies has synergized with standard of care to improve patient outcomes in both newly diagnosed MM as well as relapsed and refractory MM. This manuscript reviews current and prospective antibody-based treatments including naked monoclonal antibodies, immunoconjugates, and Bi-specific T-cell engagers (BiTE).",

keywords = "Belantamab, BiTE, Daratumumab, Elotuzumab, Immunoconjugates, Isatuximab, Monoclonal antibody, Multiple myeloma",

author = "Emily Bryer and Christin DeStefano and Dickran Kazandjian",

note = "Publisher Copyright: {\textcopyright} 2021",

year = "2022",

month = feb,

doi = "10.1053/j.seminoncol.2021.11.002",

language = "English",

volume = "49",

pages = "41--47",

journal = "Seminars in Oncology",

issn = "0093-7754",

number = "1",

}

TY - JOUR

T1 - Current and prospective antibody-based therapies in multiple myeloma

AU - Bryer, Emily

AU - DeStefano, Christin

AU - Kazandjian, Dickran

PY - 2022/2

Y1 - 2022/2

N2 - Multiple Myeloma (MM) is a hematologic malignancy involving clonal plasma cell proliferation. Unfortunately, MM remains an incurable disease. Over the past five years, the incorporation of novel monoclonal antibodies has synergized with standard of care to improve patient outcomes in both newly diagnosed MM as well as relapsed and refractory MM. This manuscript reviews current and prospective antibody-based treatments including naked monoclonal antibodies, immunoconjugates, and Bi-specific T-cell engagers (BiTE).

AB - Multiple Myeloma (MM) is a hematologic malignancy involving clonal plasma cell proliferation. Unfortunately, MM remains an incurable disease. Over the past five years, the incorporation of novel monoclonal antibodies has synergized with standard of care to improve patient outcomes in both newly diagnosed MM as well as relapsed and refractory MM. This manuscript reviews current and prospective antibody-based treatments including naked monoclonal antibodies, immunoconjugates, and Bi-specific T-cell engagers (BiTE).

KW - Belantamab

KW - BiTE

KW - Daratumumab

KW - Elotuzumab

KW - Immunoconjugates

KW - Isatuximab

KW - Monoclonal antibody

KW - Multiple myeloma

UR - http://www.scopus.com/inward/record.url?scp=85122261624&partnerID=8YFLogxK

U2 - 10.1053/j.seminoncol.2021.11.002

DO - 10.1053/j.seminoncol.2021.11.002

M3 - Article

C2 - 34996619

AN - SCOPUS:85122261624

SN - 0093-7754

VL - 49

SP - 41

EP - 47

JO - Seminars in Oncology

JF - Seminars in Oncology

IS - 1

ER -

Current and prospective antibody-based therapies in multiple myeloma

Abstract

Keywords

Access to Document

Fingerprint

Cite this